HB3355 102ND GENERAL ASSEMBLY

  
  

 


 
102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022
HB3355

 

Introduced 2/22/2021, by Rep. Charles Meier

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/315.6 new

    Amends the Illinois Controlled Substances Act. Provides that a prescriber who is licensed to prescribe controlled substances shall, prior to issuing a prescription for an opioid that is a Schedule II controlled substance, discuss with a patient who is under 18 years of age and is an emancipated minor, or with the patient's parent or guardian if the patient is under 18 years of age and is not an emancipated minor, the risks of developing a physical or psychological dependence on the opioid and, if the prescriber deems it appropriate, any alternative treatments as may be available. Provides that a prescriber who engages in a discussion required under this provision shall include a note in the patient's medical record indicating that the discussion took place. Provides that the discussion required under this provision shall not be required prior to issuing a prescription to any patient who is currently receiving hospice care from a comprehensive hospice licensed under the Hospice Program Licensing Act. Effective immediately.


LRB102 16962 RLC 22380 b

 

 

A BILL FOR

 

HB3355LRB102 16962 RLC 22380 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by adding Section 315.6 as follows:
 
6    (720 ILCS 570/315.6 new)
7    Sec. 315.6. Prescriber to discuss risks of dependence on
8opioids with certain patients.
9    (a) In this Section, "opioid" means a narcotic drug or
10substance that is a Schedule II controlled substance under
11paragraph (1), (2), (3), or (5) of subsection (b) or under
12subsection (c) of Section 206 of this Act.
13    (b) A prescriber who is licensed to prescribe controlled
14substances shall, prior to issuing a prescription for an
15opioid that is a Schedule II controlled substance, discuss
16with a patient who is under 18 years of age and is an
17emancipated minor, or with the patient's parent or guardian if
18the patient is under 18 years of age and is not an emancipated
19minor, the risks of developing a physical or psychological
20dependence on the opioid and, if the prescriber deems it
21appropriate, any alternative treatments as may be available.
22    (c) A prescriber who engages in a discussion required
23under subsection (b) shall include a note in the patient's

 

 

HB3355- 2 -LRB102 16962 RLC 22380 b

1medical record indicating that the discussion took place.
2    (d) The discussion required under subsection (b) shall not
3be required prior to issuing a prescription to any patient who
4is currently receiving hospice care from a comprehensive
5hospice licensed under the Hospice Program Licensing Act.
 
6    Section 99. Effective date. This Act takes effect upon
7becoming law.